title: Effect of hypoglycemic drugs on aspirin resistance in patients with diabetes mellitus.
abstract: BACKGROUND
  Aspirin reduces the odds of an arterial thrombotic event in high-risk patients. However, 10%-20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term followup. Aspirin resistance has been described in some patient populations such as those with an acute coronary syndrome, ischemic stroke, percutaneous coronary intervention with drug-eluting stent, stent re-stenosis, and diabetes mellitus (DM). The aim of this study was to assess aspirin resistance and to compare it to the use of oral anti-diabetic drugs and insulin in patients with diabetes.
  
  
  RESULTS
  Platelet aggregation was measured after aspirin treatment in 101 diabetic patients undergoing percutaneous coronary intervention. Two patient populations were included in the investigation: use of insulin (group 1) and use of oral anti-diabetic agents (OAD) (group 2) in diabetic patients. Platelet aggregation was determined using a multichannel Multiplate analyzer. Among group 1 patients, 4.7% were aspirin non-responders and among group 2 patients, 8.6% were aspirin non-responders. Statistical differences were not found between the groups (p = 0.359).
  
  
  CONCLUSIONS
  This study demonstrated that there was no significant difference in aspirin resistance between type 2 diabetes mellitus patients on insulin treatment and type 2 diabetes mellitus patients on OAD treatment.
authors: Department of Cardiology, Medicine Faculty, Dicle University Diyarbakir, Turkey. zariturk@yahoo.com
authors: Z
authors: Z
authors: Ariturk
authors: Y
authors: Y
authors: Islamoglu
authors: E
authors: E
authors: Gündüz
authors: C
authors: C
authors: Yavuz
authors: H
authors: H
authors: Cil
authors: E
authors: E
authors: Tekbas
authors: S
authors: S
authors: Soydinc
authors: H
authors: H
authors: Kaya
authors: M A
authors: MA
authors: Elbey
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011446:Prospective Studies; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D017211:Treatment Failure; D014421:Turkey
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin